Sun Pharma revises upwards price to fully acquire Taro to USD 43 per share

In May this year, Sun Pharmaceutical Industries announced a non-binding indication of interest to acquire all of the outstanding ordinary shares of Taro for a purchase price of USD 38 per ordinary share in cash through a reverse triangular merger.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news